The 4 most recent market catalysts affecting $MPHA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 85
Medicus Pharma Says CD228V ADC Now Principal Strategic Priority, With Initial Development In Relapsed Or Refractory Melanoma; Says FDA Authorized Initiation Of Registrational Phase 2b SkinJect Study In Gorlin Syndrome
The announcement of CD228V ADC as a principal strategic priority, coupled with the FDA's authorization for a registrational Phase 2b study, is a major positive catalyst for Medicus…
Sep 3, 2026
Corporate Catalyst
Bearish
Impact 85
Medicus Pharma shares are trading lower after the company announced a co‑development and license agreement for CD228V with Pfizer that requires significant upfront payments.
This headline is a significant corporate catalyst for Medicus Pharma (MPHA). The requirement for 'significant upfront payments' immediately raises concerns about MPHA's cash flow a…
Jul 27, 2026
Corporate Catalyst
Bullish
Impact 85
Medicus Pharma Receives FDA Approval To Proceed With Phase 2b Clinical Study Of SkinJect 200 Mcg To Treat Patients With Gorlin Syndrome Presenting With Multiple Basal Cell Carcinomas
The FDA's approval to proceed with a Phase 2b clinical study is a crucial milestone for Medicus Pharma, significantly de-risking SkinJect 200 mcg's development. This positive news …
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 85
Medicus Pharma shares are trading higher after the company announced that it has received written feedback from the FDA and central Institutional Review Board approval, with modifications, for its optimized Phase 2 clinical study of Teverelix in men following a first episode of acute urinary retention.
This headline represents a significant positive catalyst for Medicus Pharma. Receiving written feedback from the FDA and IRB approval, even with modifications, indicates that the T…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.